-+ 0.00%
-+ 0.00%
-+ 0.00%

Knight Therapeutics wins Brazil ANVISA approval for NIKTIMVO to treat chronic GVHD

PUBT·10/06/2026 11:35:18
Listen to the news
Knight Therapeutics wins Brazil ANVISA approval for NIKTIMVO to treat chronic GVHD
  • Knight Therapeutics received expedited ANVISA rare-disease clearance in Brazil for NIKTIMVO (axatilimab) to treat chronic GVHD.
  • Label covers adults, pediatric patients aged 6+ weighing at least 40 kg, following failure of at least two systemic therapies.
  • Approval supports Knight’s Latin America distribution deal with Incyte, which supplies the product.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Knight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060735PRIMZONEFULLFEED9840166) on October 06, 2026, and is solely responsible for the information contained therein.